Banco Bilbao Vizcaya Argentaria S.A. Has $25.28 Million Holdings in Stryker Corporation $SYK

Banco Bilbao Vizcaya Argentaria S.A. increased its holdings in shares of Stryker Corporation (NYSE:SYK) by 15.5% during the fourth quarter, Holdings Channel reports. The fund owned 71,853 shares of the medical technology company’s stock after acquiring an additional 9,655 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Stryker were worth $25,279,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in shares of Stryker by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock valued at $11,917,396,000 after purchasing an additional 133,892 shares during the period. State Street Corp boosted its holdings in shares of Stryker by 2.1% during the fourth quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock worth $5,374,731,000 after acquiring an additional 311,507 shares during the period. Geode Capital Management LLC grew its position in shares of Stryker by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock valued at $2,636,238,000 after purchasing an additional 69,851 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in Stryker by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after purchasing an additional 741,542 shares during the last quarter. Finally, Norges Bank bought a new stake in Stryker in the 4th quarter valued at $1,822,272,000. 77.09% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on SYK shares. Needham & Company LLC dropped their target price on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a report on Friday, May 1st. Barclays cut their price objective on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a report on Monday, May 4th. Wall Street Zen cut shares of Stryker from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Canaccord Genuity Group reduced their price target on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Finally, JPMorgan Chase & Co. cut their target price on Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Sixteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus price target of $395.33.

Stryker Stock Performance

NYSE SYK opened at $301.24 on Thursday. The firm’s fifty day moving average price is $314.89 and its two-hundred day moving average price is $342.38. The stock has a market cap of $115.48 billion, a PE ratio of 34.87, a PEG ratio of 1.99 and a beta of 0.78. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities analysts expect that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is presently 40.74%.

Insider Activity

In other news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 323,264 shares of company stock valued at $100,659,489. Insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.